Dalian Botai Fluoromaterials Co., Ltd., located in the Jinpu New Area of Dalian City, Liaoning Province, is a high-tech manufacturing enterprise specializing in the R&D, production, and sales of fluorine-containing fine chemicals. Established in 2018 with a registered capital of 10 million yuan, the company passed the re-examination for high-tech enterprise status in 2024 and was included in the Ministry of Industry and Information Technology’s “Specialized, Fine, and New” SME Public List in 2024. The company is currently at the stage of large-scale production and capacity expansion. Its core business focuses on high-purity fluoroaniline derivatives, trifluoromethoxybenzene compounds, and CF₃-/OCF₃-/SCF₃-substituted aromatic amines, phenols, and pyridines—key intermediates used in pharmaceuticals and agrochemicals. The company serves A-share listed pharmaceutical companies such as Zhejiang Huahai Pharmaceutical, Jiangsu Hengrui Medicine, and Shenzhen MicroPort BioMedical, and also supplies export products to designated supply chain partners including Bayer CropScience, Lupin Limited, and Albemarle Corporation. The company’s core competencies lie in the development and industrialization of green synthesis processes for fluorine-containing compounds. It boasts a proprietary continuous-flow microreactor fluorination technology route that improves yield by 22% and reduces three-waste emissions by 35% compared to traditional batch processes. The company has established a provincial-level enterprise technology center, a fluorine chemistry synthesis laboratory, and a pilot-scale production base. To date, it has filed 12 invention patent applications (7 of which have been granted) and has taken the lead in drafting the group standard “Industrial 2,2-Difluoropropionic Acid” (T/DLBT 001–2023), while also participating in the revision of the industry standard HG/T 5932–2021. In terms of certifications, the company holds ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 management system certifications (issued by SGS, valid until 2026). It has successfully passed an on-site audit by the U.S. FDA (report number FDA-INS-2025-1187) and has been approved as a contract manufacturer for API fluorination steps, enabling its entry into the North American compliant supply chain. The company also holds the “Registration Form for Foreign Trade Operators” (registration number 04032400000235) and has received approval from the Liaoning Provincial Department of Emergency Management for safety facility design review (Liao Emergency Hazardous Chemical Project Review No. [2022] 089). Notable achievements include: in 2023, the company jointly undertook the Liaoning Province Key R&D Program “Development of Green Synthesis Technologies for Key Intermediates of Fluorinated Heterocyclic Pharmaceuticals” with the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, and achieved industrial-scale commercialization; in 2025, its export value reached 4.28 million U.S. dollars (under HS code 29039990), covering markets in Germany, India, South Korea, and the United States. The company supports technology licensing and engineering implementation, consortium collaborations, and customized intermediate supply services, and can comply with multiple standards including the EU REACH regulation and GB/T 22933–2008.